[ij] [ij] [ij] 
Email id

Asian Journal of Pharmaceutical Research
Year : 2016, Volume : 6, Issue : 1
First page : ( 45) Last page : ( 50)
Print ISSN : 2231-5683. Online ISSN : 2231-5691.
Article DOI : 10.5958/2231-5713.2016.00007.6

Pharmacology of combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease

Krishna V. Prajapati1,*, Dr. Vinit C. Jain1, Ms. Neelam Prajapati2

1Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat

2Assistant Professor, Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat

*Corresponding Author E-mail: krish1112k@gmail.com

Online published on 2 April, 2016.


This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is as used in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.



Mesalazine, Rifaximin, inflammatory bowel disease, Pharmacology.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
751,826,863 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.